HLB Life Science

067630 · KOSDAQ · Health Care · SMALL CAP

Early redemption of convertible bonds (incl. overseas CBs)

HLB Life Science Co., Ltd. acquired US$3.53M face value of its Series 13 convertible bonds (issued 2024-08-29, maturing 2027-08-29, conversion price US$5.65 per share) on 2026-08-14 for US$3.61M (principal plus interest) by separate agreement with the bondholder, via over-the-counter purchase, leaving US$847K of the bonds outstanding; future treatment is to be determined by the board.

Capital raise(Early redemption of convertible bonds (incl. overseas CBs))· FILED 2026-08-14· RCEPT 20260814901315

What happened

HLB Life Science / Early Redemption of Convertible Bonds (Including Overseas CBs) Prior to Maturity / (2026.08.14)

Early Redemption of Convertible Bonds (Including Overseas CBs) Prior to Maturity (Series 13)

Convertible Bonds (Including Overseas CBs), Series 13

1. Matters concerning the bonds acquired prior to maturity Type of bonds: Unregistered (bearer-form), unsecured, privately placed convertible bonds Issuance date: 2024-08-29 Issuance method: Domestic issuance (private placement) Conversion price per share (KRW): 8,008 Maturity date: 2027-08-29

2. Bond acquisition amount (currency): 5,110,120,000 KRW: South Korean Won - Face (electronically registered) total amount of bonds acquired (currency): 5,000,000,000 KRW: South Korean Won - Applicable exchange rate: - - Acquisition date: 2026-08-14

3. Total face (electronically registered) amount of bonds outstanding after acquisition (currency): 1,200,000,000 KRW: South Korean Won

4. Reason for acquisition prior to maturity and future treatment - Reason for acquisition prior to maturity: Acquisition of the bonds pursuant to a separate agreement with the bondholder - Future treatment plan: To be determined through a future board resolution

5. Source of acquisition funds: Own funds

6. Method of bond acquisition: Over-the-counter purchase

7. Other matters for investment reference - Item 2, "Bond acquisition amount," above includes both the principal and interest of these bonds. - Item 3, "Total face (electronically registered) amount of bonds outstanding after acquisition," above is the total amount of unconverted convertible bonds held by bondholders after excluding this acquisition. - The "acquisition date" above is the date of payment of the acquisition amount.

* Related disclosures: 2024-08-21 Decision to Issue Convertible Bonds (Series 13) 2024-11-29 Adjustment of Conversion Price 2025-02-28 Adjustment of Conversion Price 2025-05-29 Adjustment of Conversion Price (Series 13) 2026-02-19 Early Redemption of Convertible Bonds (Including Overseas CBs) Prior to Maturity (Series 13) 2026-02-25 Early Redemption of Convertible Bonds (Including Overseas CBs) Prior to Maturity (Series 13) 2026-03-03 Early Redemption of Convertible Bonds (Including Overseas CBs) Prior to Maturity (Series 13) 2026-05-29 Early Redemption of Convertible Bonds (Including Overseas CBs) Prior to Maturity (Series 13) 2026-06-18 Early Redemption of Convertible Bonds (Including Overseas CBs) Prior to Maturity (Series 13)

Filed2026-08-14, Early redemption of convertible bonds (incl. overseas CBs)
SourceDART rcept 20260814901315 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-08-14 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).